The US-based foundation Fighting Blindness has pledged to fund vision research at Radboudumc and the Donders Institute with a total sum of five million dollars. The funds will be used to develop therapies for hereditary diseases of the retina and Usher syndrome.There are thousands of children and adults in the Netherlands affected by hereditary diseases of the retina. These are conditions for which - until this day - treatment is elusive. At Radboudumc and the Donders Institute, several research groups are working to develop new therapies with which these conditions can be treated.
The first project is a collaboration between the departments of genetics, ENT, and opthalmology, and aims to find genetic errors that lead to abnormalities in messenger RNA (mRNA). Frans Cremers, professor of Blindness Genetics and coordinator of the project: "mRNA translates DNA to proteins. We developed a 'genetic bandaid' that can patch errors in mRNA, which leads them to produce functioning proteins again. With the new funding we are going to improve this technique and test it in animal models. Thereby, we hope to eventually develop experimental treatments for patients suffering from retinitis pigmentosa, Stargardt's disease, and Usher syndrome. These are all diseases where these types of genetic errors occur."
In the second project, the department of Genetics will collaborate with universities in London, Mainz, and Tübingen. Work in cells, and thus also in the retinal cells in the eye, is performed by proteins. To perform its various duties, every cell maintains a dynamic balance of different active proteins. "We want to unravel the mechanisms by which the amount of active proteins is regulated within a retinal cell", says Ronald Roepman, professor of Genetics and coordinator of this project. "This regulation is disturbed in hereditary diseases of the eye. The knowledge that we are going to obtain can be used to develop medication to counter counter these disturbances. This way, we aim to stop the progression of blindness in patients".
Two out of three
The US-based faoundation Fighting Blindness has approved a total of three of these large funds this year, of which two were awarded to research groups in Nijmegen.
Related news items
The Postdoctoral Networking Tour in artificial intelligence2 July 2020
You are a postdoctoral researcher in the field of artificial intelligence? The Postdoc-NeT-AI offers you the opportunity to participate in one week of on-site visits to leading German universities, research institutes and companies. Apply now to this year's tour until 16 August 2020.read more
Register for Phd courses via gROW What does this mean for you?2 July 2020
From now on you can arrange everything related to the general RU PhD courses via gROW. Because of this there will be some changes in the registration! What does this mean for you?read more
Experts on metabolic diseases still an unknown major problem...1 July 2020
Six Dutch UMCs and a patient association contribute to treating and solving this major, often unknown, problem. Timely detection of metabolic diseases is vital. Therefore, Radboudumc is also part of the consortium “United for Metabolic Diseases”.read more
Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute30 June 2020
Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.read more
Stefan Listl member Lancet Commission on Oral Health29 June 2020
In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection29 June 2020
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more